BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SJ, Choi MS, Kang JY, Choi DI, Park CK, Gwak GY, Lee JH, Koh KC, Paik SW, Yoo BC. Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. Gut Liver 2009;3:285-91. [PMID: 20431762 DOI: 10.5009/gnl.2009.3.4.285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019;9:3674-86. [PMID: 31281506 DOI: 10.7150/thno.32943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
2 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
3 Zheng J, Sun B, Liu D, Yan L, Wang Y. Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectin(low) CXCR3+ CD8+ T cell subset in patients with hepatocellular carcinoma. Onco Targets Ther 2012;5:103-9. [PMID: 22719212 DOI: 10.2147/OTT.S31816] [Reference Citation Analysis]
4 Bisseret D, Ronot M, Abdel-rehim M, Sibert A, Bouattour M, Castera L, Belghiti J, Vilgrain V. Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. Journal of Vascular and Interventional Radiology 2013;24:1623-31. [DOI: 10.1016/j.jvir.2013.07.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Sci Rep 2020;10:18026. [PMID: 33093524 DOI: 10.1038/s41598-020-75120-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 2014;97:220-6. [PMID: 24056629 DOI: 10.1097/TP.0b013e3182a8607e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lee JE, Kim JW, Kim HO, Lee BC, Hur YH, Cho SB, Cho YS, Seon HJ, Kim D. Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma: Does the Degree of Ethiodized Oil Accumulation within the Tumor Affect the Therapeutic Efficacy? J Vasc Interv Radiol 2019;30:370-379.e4. [PMID: 30819479 DOI: 10.1016/j.jvir.2018.09.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Lerut J, Julliard O, Ciccarelli O, Lannoy V, Gofette P. Hepatocellular cancer and liver transplantation: a Western experience. Recent Results Cancer Res 2013;190:127-44. [PMID: 22941018 DOI: 10.1007/978-3-642-16037-0_9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 2020;13:100742. [PMID: 32092672 DOI: 10.1016/j.tranon.2020.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
10 Gaba RC, Baumgarten S, Omene BO, van Breemen RB, Garcia KD, Larson AC, Omary RA. Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. J Vasc Interv Radiol 2012;23:265-73. [PMID: 22178040 DOI: 10.1016/j.jvir.2011.10.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
11 Henry JC, Malhotra L, Khabiri H, Guy G, Michaels A, Hanje J, Azevedo M, Bloomston M, Schmidt CR. Best radiological response to trans-arterial chemoembolization for hepatocellular carcinoma does not imply better outcomes. HPB (Oxford) 2013;15:196-202. [PMID: 23374360 DOI: 10.1111/j.1477-2574.2012.00529.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530-549. [PMID: 23921081 DOI: 10.1016/j.critrevonc.2013.07.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
13 Lee DH, Lee JM, Kim PN, Jang YJ, Kang TW, Rhim H, Seo JW, Lee YJ. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. Eur Radiol 2019;29:5052-62. [PMID: 30770968 DOI: 10.1007/s00330-018-5993-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Koh YH, Choi JI, Kim HB, Kim MJ. Computed tomographic-guided radiofrequency ablation of recurrent or residual hepatocellular carcinomas around retained iodized oil after transarterial chemoembolization. Korean J Radiol 2013;14:733-42. [PMID: 24043966 DOI: 10.3348/kjr.2013.14.5.733] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
15 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]